- TLDR Biotech
- Archive
- Page 9
The Latest Biotech & Pharma Updates
Biotech & Pharma Updates | December 11 - 12, 2024
Investors sue BMS on alleged reneging on milestone payments, Novo Nordisk's Ozempic lands kidney disease-related label expansion in the EU, Expression Therapeutics has “promising” Ph1 hemophilia A gene therapy data, Keros Therapeutics stock plummets on PAH clinical trial holds due to pericardial effusion cases + 32 more stories
Biotech & Pharma Updates | December 10 - 11, 2024
Pair of (former) biotech CEOs convicted of fraud, Candel Therapeutics stock jumps on positive viral immunotherapy Ph3 data in prostate cancer, Angitia Biopharmaceuticals $120M Series C targeting musculoskeletal disorders, Q32 Bio stock collapses on "messy" trial results + 37 more stories
Biotech & Pharma Updates | December 9 - 10, 2024
uniQure stock skyrockets on clear(er) path to accelerated approval, BioNTech's breast cancer bispecific dreams of dethroning Keytruda, Tasca Therapeutics launches with $52M to discover novel lipid-bound protein pockets, GSK and Relation partner on fibrotic disease and osteoarthritis drug discovery + 33 more stories
Biotech & Pharma Updates | December 8 - 9, 2024
Gotta catch'em all (hematology clinical updates) at ASH 2024, Dimension's $500M second fund at the “interfaces of life science and technology”, Citryll's €85M Series B fuels inflammatory disease ambitions, Agios' discloses liver injuries from "very safe" mitapivat + 37 more stories
Biotech & Pharma Updates | December 5 - 8, 2024
Novo Holdings' Catalent acquisition gets go-ahead from EU regulators, Teva & Takeda divest generics joint venture to PE firm, bluebird bio touts positive long-term sickle cell disease gene therapy data, National Resilience layoffs + 24 more stories
Biotech & Pharma Updates | December 4 - 5, 2024
Atlas Venture closes $450M Fund XIV focused on biotech, Protara Therapeutics positive Ph2 cell therapy data launches stock upward, Nuvig Therapeutics $161M Series B for non-immune system suppressing autoimmune therapies, Eli Lilly & Amgen both announce $1B+ facility builds + 20 more stories
Biotech & Pharma Updates | December 3 - 4, 2024
Eli Lilly's Zepbound beats Novo Nordisk's Wegovy in obesity head-to-head, Merus' mAb Bizengri nabs pancreatic and lung cancer approvals, Antag Therapeutics joins the obesity race with an $84M Series A, Novo Nordisk buys Novavax manufacturing site + 34 more stories
Biotech & Pharma Updates | December 2 - 3, 2024
Maze Therapeutics $115M Series D fuels kidney disease ambitions, Gilead buys ADC discovery option from Tubulis, Janux T-cell engager Ph1b dose escalation data launches stock 50%, GSK's hep B vaccine hopeful sputters in Ph1/2, insult to injury as Applied Therapeutics handed FDA warning letter + 29 more stories
Biotech & Pharma Updates | December 1 - 2, 2024
Novartis signs up to $3B deal for PTC Huntington's asset, Senti Bio's stock launches 400%+ on early Ph1 CAR-NK data, Sanofi earmarks €1B for Beijing-based insulin manufacturing plant, KisoJi lands $41M in equity fuel for TROP2-targeting solid tumor clinical asset + 25 more stories
Biotech & Pharma Updates | November 25 - 26, 2024
Roche paying a pretty penny for Poseida's allogeneic cell therapy ambitions, Amgen's MariTide weight loss Ph2 data isn't enough for investors, Cradle Bio $73M Series B for AI-driven protein design, Roche’s anti-TIGIT mAb misses in lung cancer Ph3 + 26 more stories
Biotech & Pharma Updates | November 24 - 25, 2024
Cassava's much-controversial Alzheimer's hopeful flunks in Ph3, Alnylam whips out the priority review voucher for cardiomyopathy asset, Adcendo's ADC hopes get $135M injection, AstraZeneca touts Truqap prostrate cancer subtype Ph3 win + 27 more stories